Modified free-living microbes, vaccine compositions and methods of use thereof
Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.
1. A method of preventing or treating a disease in a host, comprising administering to the host an effective amount of a vaccine comprising a modified Listeria monocytogenes bacterium, wherein the modified bacterium comprises (i) psoralen-induced interstrand crosslinks introduced between the strands of genomic DNA double helix, said interstrand crosslinks inhibiting replication of said modified bacterium (ii) one or more genetic mutations in uvrA and uvrB genes inhibiting excision repair of said interstrand crosslinks, and (iii) a nucleic acid sequence encoding a polypeptide heterologous to said Listeria monocytogenes bacterium operably linked to a promoter sequence directing expression of the heterologous polypeptide by the modified bacterium.
2. A method of inducing an immune response in a host to an antigen comprising administering to the host an effective amount of a vaccine comprising a modified Listeria monocytogenes bacterium, wherein the modified bacterium comprises (i) psoralen-induced interstrand crosslinks introduced between the strands of genomic DNA double helix, said interstrand crosslinks inhibiting replication of said modified bacterium, (ii) one or more genetic mutations in uvrA and uvrB genes inhibiting excision repair of said interstrand crosslinks, and (iii) a nucleic acid sequence encoding the antigen operably linked to a promoter sequence directing expression of the antigen by the modified bacterium, wherein said antigen is heterologous to said Listeria monocytogenes bacterium.
3. The method of claim 1 , wherein the interstrand crosslinks are introduced by reaction with 4′-(4-amino-2-oxa)butyl-4,5′,8-trimethylpsoralen activated by irradiation.
4. The method of claim 1 , wherein the genetic mutations in uvr gene(s) comprise deletions in the uvrA and uvrB, genes such that the modified bacterium does not produce functional uvrA and uvrB gene products.
5. The method of claim 1 , wherein the vaccine further comprises a pharmaceutically acceptable carrier or an adjuvant.
6. The method of claim 1 , wherein the bacterial gene expression of the bacterium is substantially unaffected by the interstrand crosslinks.
7. The method of claim 1 , wherein the disease is an infectious disease.
8. The method of claim 1 , wherein the disease is cancer.
9. The method of claim 2 , wherein the interstrand crosslinks are introduced by reaction with 4′-(4-amino-2-oxa)butyl-4,5′,8-trimethylpsoralen activated by irradiation.
10. The method of claim 2 , wherein the genetic mutations in uvr gene(s) comprise deletions in the uvrA and uvrB, genes such that the modified bacterium does not produce functional uvrA and uvrB gene products.
11. The method of claim 2 , wherein the vaccine further comprises a pharmaceutically acceptable carrier or an adjuvant.
12. The method of claim 2 , wherein the bacterial gene expression of the bacterium is substantially unaffected by the interstrand crosslinks.
13. The method of claim 2 , wherein the antigen is a tumor antigen.
14. The method of claim 13 , wherein the tumor antigen is mesothelin, SPAS-1, proteinase-3, SP-17, gp100, PAGE-4, TARP, Her-2/neu, WT-1, NY-ESO-1, PSMA, K-ras, survivin, mcm-2, or CEA, or an antigen derived from mesothelin, SPAS-1, proteinase-3, SP-17, gp100, PAGE-4, TARP, Her-2/neu, WT-1, NY-ESO-1, PSMA, K-ras or CEA.
15. The method of claim 2 , wherein the antigen is an infectious disease antigen.
16. The method of claim 15 , wherein the antigen is derived from a Human Immundeficiency Virus or a hepatitis virus.
17. The method of claim 16 , wherein the antigen is derived from hepatitis C virus.